In a press release on March 6, 2023, Invitae announces that it has won coverage for its minimal residual disease assay (MRD), in all solid cancers, from Blue Shield of California. The assay, based on customized testing of the patient's circulating tumor DNA, is called Invitae PCM(tm) (Personalized Cancer Monitoring).
Find the press release here. Find coverage at Genomeweb here.
Commercial payers are moving on MRD, which garnered MolDx coverage just over a year ago. See recent news on Natera and Blue Shield of California here.
